Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, Jean-François Bosset et al.|The Lancet Oncology|2021Cited by 1.3k
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancerEmmanouil Fokas, Claus Rödel, Corrie A.M. Marijnen et al.|Nature Reviews Clinical Oncology|2021Cited by 242
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.Thierry Conroy, Christophe Borg, Najib Lamfichekh et al.|Journal of Clinical Oncology|2020Cited by 177
Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II studyH.J.T. Rutten, Philip Quirke, David Sebag‐Montefiore et al.|Journal of Clinical Oncology|2006Cited by 74